Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies in patients with hyperthyroidism due to Graves’ disease

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves’ disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Official Title

Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Conditions

Graves’ Ophthalmopathy

Study Type

Interventional

Study Design

Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Further Details

Primary Outcome Measures: Onset or progression of ophthalmopathy following radio-active iodine therapy

Study Start

August 2003; Study completion: January 2006

Eligibility & Criteria

• Ages Eligible for Study: 18 Years and above
• Genders Eligible for Study: Both

Inclusion Criteria:

• Graves’ disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion Criteria:

• Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
• Age < 18 years
• Inability to consent to participation in the study
• Pregnancy
• History of radio-active iodine therapy

Total Enrolment

60

Contact Details

Barwon Health – The Geelong Hospital, Geelong, Victoria, 3220, Australia